As we observed that CD133/PROM1HIGH patient-derived GBM cells demonstrated increased glycolytic function as compared to CD133/PROM1LOW GBM cells, we further explored their differences in mitochondrial metabolic activity. The gene discussed is PROM1; the disease is glioblastoma.